Show simple item record

dc.contributor.authorCraig, Andrew P
dc.contributor.authorGray, Richard T
dc.contributor.authorEdwards, Jennifer L
dc.contributor.authorApicella, Michael A
dc.contributor.authorJennings, Michael P
dc.contributor.authorWilson, David P
dc.contributor.authorSeib, Kate L
dc.date.accessioned2017-08-04T07:06:35Z
dc.date.available2017-08-04T07:06:35Z
dc.date.issued2015
dc.identifier.issn0264-410X
dc.identifier.doi10.1016/j.vaccine.2015.07.015
dc.identifier.urihttp://hdl.handle.net/10072/124986
dc.description.abstractGonorrhea, one of the most common sexually transmitted infections worldwide, can lead to serious sequelae, including infertility and increased HIV transmission. Recently, untreatable, multidrug-resistant Neisseria gonorrhoeae strains have been reported. In the absence of new antibiotics, and given the speed with which resistance has emerged to all previously used antibiotics, development of a vaccine would be the ideal solution to this public health emergency. Understanding the desired characteristics, target population, and expected impact of an anti-gonococcal vaccine is essential to facilitate vaccine design, assessment and implementation. The modeling presented herein aims to fill these conceptual gaps, and inform future gonococcal vaccine development. Using an individual-based, epidemiological simulation model, gonococcal prevalence was simulated in a heterosexual population of 100,000 individuals after the introduction of vaccines with varied efficacy (10–100%) and duration of protection (2.5–20 years). Model simulations predict that gonococcal prevalence could be reduced by at least 90% after 20 years, if all 13-year-olds were given a non-waning vaccine with 50% efficacy, or a vaccine with 100% efficacy that wanes after 7.5 years. A 40% reduction in prevalence is achievable with a non-waning vaccine of only 20% efficacy. We conclude that a vaccine of moderate efficacy and duration could have a substantive impact on gonococcal prevalence, and disease sequelae, if coverage is high and protection lasts over the highest risk period (i.e., most sexual partner change) among young people.
dc.description.peerreviewedYes
dc.languageEnglish
dc.language.isoeng
dc.publisherElsevier
dc.relation.ispartofpagefrom4520
dc.relation.ispartofpageto4525
dc.relation.ispartofissue36
dc.relation.ispartofjournalVaccine
dc.relation.ispartofvolume33
dc.subject.fieldofresearchBiological sciences
dc.subject.fieldofresearchAgricultural, veterinary and food sciences
dc.subject.fieldofresearchBiomedical and clinical sciences
dc.subject.fieldofresearchImmunology not elsewhere classified
dc.subject.fieldofresearchHealth sciences
dc.subject.fieldofresearchcode31
dc.subject.fieldofresearchcode30
dc.subject.fieldofresearchcode32
dc.subject.fieldofresearchcode320499
dc.subject.fieldofresearchcode42
dc.titleThe potential impact of vaccination on the prevalence of gonorrhea
dc.typeJournal article
dc.type.descriptionC1 - Articles
dc.type.codeC - Journal Articles
dcterms.licensehttp://creativecommons.org/licenses/by-nc-nd/4.0/
dc.description.versionVersion of Record (VoR)
gro.rights.copyright© 2015 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/) which permits unrestricted, non-commercial use, distribution and reproduction in any medium, providing that the work is properly cited. You may not alter, transform, or build upon this work.
gro.hasfulltextFull Text
gro.griffith.authorJennings, Michael P.
gro.griffith.authorSeib, Kate


Files in this item

This item appears in the following Collection(s)

  • Journal articles
    Contains articles published by Griffith authors in scholarly journals.

Show simple item record